Leisure, Lifestyle & Wellness
Trial results proves skeptics of Chelation Therapy wrong

Recent research data which was partially announced has proven critics wrong. BV Gokhale writes about the history of chelation therapy, the results of the TACT trials and the politics of it all

Chelation therapy, an alternative to angioplasty and bypass surgery, had constantly been given a bad rep by mainstream doctors due to its low cost which hardly earns any revenues (vis-à-vis angioplasty and bypass). Moreover, skeptics had branded it as ‘unsafe’ and ‘dangerous’. However, empirical results assessing the safety of Chelation Therapy that were partially declared recently has shown the opposite—Chelation can be successful.  


To learn more about Chelation Therapy, click here to view the video of BV Gokhale’s seminar at Moneylife Foundation on Moneylife TV.


Pioneering efforts by cardiologist Dr Norman Clarke gave a very sound proof of the efficacy of EDTA Chelation Therapy in reversal of coronary artery disease. Later, till 1964, many others researchers consolidated this hypothesis. Soon heart bypass surgery was born. Without any proving trial, people were led to (mis)believe, through media propaganda, that it gives second birth to the patient and extends his life span. Many who thought that the end of their life was near quickly underwent this dangerous surgery.


Cardiac surgeons started using this tool in hugely increasing income through media propaganda. Chelation Therapy, an inexpensive and simple procedure, was proving as an obstacle. Naturally, attempts to brand it dangerous and ineffective started and consolidated when cardiologists got another money spinning tool in angioplasty. In 1978, United States Food and Drug Administration (US FDA) made felon attempt to ban EDTA Chelation Therapy. However, Dr Ray Evers fought the battle and kept it alive.


Even today, after successful treatment of several million patients all over the world, tirade against Chelation Therapy continues.


In the decades of 1980 and 1990 many more patients started turning towards Chelation Therapy. Doctors providing Chelation Therapy were always looked upon as criminals by the US FDA and were either harassed or arrested. To overcome all these troubles, groups of patients and American College of Alternative Medicine (ACAM), made agitations. After listing to the woes of these agitators, Senator Dan Burton held a hearing in 1999 and recommended that an appropriate trial be conducted by National Institute of Health (NIH), to assess the safety and efficacy of Chelation Therapy.


Despite the research being expensive, Senator Burton insisted upon and got a grant of $30 million.


The trial, named Trial to Assess Chelation Therapy (TACT), was started by NIH in the year 2003. Being related to coronary artery disease, the controllers of the trial were chosen from AHA, a known anti-Chelation organization. Protocol was finalized in consultation with ACAM.


For enrollment of patients, actual administration of the Chelation drips and to collect patient information from time to time, help of about 100 doctors operating chelation clinics at 134 locations was taken.


In order to stay away from mainstream medicine, the trial progressed at a snail’s pace but without much trouble otherwise, probably because the anti-Chelation lobby was confident that the results will actually show Chelation Therapy to be at least ineffective if not dangerous. However, by 2008, information was leaked and the anti-Chelation lobby realised that actually the trial was proving Chelation to be safe and effective. So the lobby, spearheaded by Dr Atwood, made vehement media attacks on the trial and made every attempt to get the trial abandoned. To resolve the issue the trial was suspended for sometime but, fortunately, Dr Gervasio Lamas, the principal investigator tackled the matter aptly and the trial was completed.


Eventually the results of TACT were partially declared in the annual meeting of AHA on 4 November 2012. Information of TACT and conclusions are as under:


TACT start date—September 2003

Fund allocation—$ 31.6 million

No. of patients—1,708

Average age—65 Years

CHD status—All the patients had previous heart attacks and 83% of them had undergone bypass surgery or angioplasty.


Of theses 839 were randomised to take 30 disodium EDTA Chelation infusions in 30 weeks and then 10 more EDTA Chelation infusions once in two to eight weeks. Remaining 869 patients were randomised to take placebo infusions in equal numbers. All patients were followed up for average duration of 55 months.


The conclusion drawn from the data collected in these trials are as under:

  1. Before starting the main study, a pilot study was conducted to reassess safety. It was noticed that after 14 infusions given to each of the 30 patients, the blood parameter, viz. creatinine, hematocrit, magnesium, platelet count and potassium remained almost unaltered. This means the likelihood of any adverse event in main trial is very low.
  1. Of the 839 patients taking Chelation infusions only one apparently died due to therapy. This means that Chelation Therapy is far safer than angioplasty or bypass surgery.
  1. The incidence of various end points in Chelation Vs placebo was as under:


End Point

Chelation Patients

Placebo Patients

Death for Any Reason



Heart Atttack






Need for Angioplasty or Bypass Surgery



Hospitalization Due to Angina



All Above Incidences Summed Up



No. of Adverse Events in Diabetic Patients




This definitely indicates that Chelation Therapy is better than placebo on EVERY aspect.

  1. Diabetic patients were greatly benefited by Chelation Therapy as they had 39% less hazard ratio of events compared to non-diabetic.

From the points 3 and 4 above it can be concluded that chelation therapy results in healthy life extension of coronary artery disease patients.


Finally, in my honest opinion due to any reasons only a tip of iceberg of benefits of Chelation Therapy was shown by the study. In actual practice, if a capable chelation physician treats patients with individualised and humane approach, he can certainly get far better results from his treatments. More about the results will be written, in detail, in a supplementary follow up to this piece.


With great regret, it must be mentioned that despite the significant benefits of Chelation Therapy, as revealed by TACT, many members of AHA are still engaged in finding non existing faults with TACT and to call it dangerous and ineffective. In most of European and other countries Chelation Therapy is not hated. Some Americans doctors will never have the consideration for society that prevails in doctors in other countries.


Click here and here to learn more about Chelation Therapy


Click here to read more about the event given by BV Gokhale held at Moneylife Foundation


(The author is a BTech and MTech (IIT Powai) and works with a team of doctors.)



Dr Sibia

4 years ago

Our experience since 1994 with chelation therapy for ischemic heart disease, cerebral ischemia and peripheral artery disease has been excellent.. My and my wife's training in MBBS and MD caused our first reaction about Chelation Therapy in 1992-1993 to be a biased negative. One of the reasons that ''forced'' me to practice Chelation therapy was when someone close to me had a coronary artery stent failure within just a couple of months. He wanted me to explore other options as he could not afford bypass surgery.
I took training and did his chelation therapy not expecting any benefit - but he made a marvelous recovery. One patient led to another. It took us three years to finally come top terms with our mental bloc\k and finally accept Chelation Therapy as an effective, safe and economical treatment. With the experience of Chelation we ventured into other non-invasive, non-surgical treatment and today when anyone wants to explore non-surgical options for any ailment they contact us.. Anyone wanting information is welcome to contact us. We do wish that there is more research on this and other non-surgical treatments and invite like minded medical and non medical persons to support our efforts.- Dr Sibia


Harold Dsouza

In Reply to Dr Sibia 2 years ago

It will be very appropriate if the patients treated by you post their views so that more people are made aware of the benefits of this method of treatment . No one will be able to counter the testimony of patients , especially those who have undergone angioplasty/bypass surgery without much result .

Dr Sibia

5 years ago

Since we introduced Chelation Therapy in India at Sibia Medical Centre, Ludhiana, in 1994 we  always considered it as a patient proven therapy that has insufficient double blind controlled studies. Our experience of probably over 100,000 intravenous infusions stands testimony to it. We believe that it is near impossible to have such a trial. Even double blind studies in bypass surgery and angioplasty are rare. The mental block against chelation therapy lies in it appearing to be such a simple solution to a complex problem. We welcome anyone to contact us on mb +91-9814034818 to visit us with an open mind and interview our patients. We have several patients who had no option due to being unfit for surgery, recurrence after bypass, failed bypass and those who could not afford bypass who have responded well to chelation therapy. Specially important is the zero mortality during the procedure. Dr Sibia

SEBI imposes Rs12 lakh fine on Roselabs Industries

Roselabs Industries was penalised for not redressing investor complaints within a stipulated time and not submitting action taken report to the market regulator

Mumbai: Market regulator Securities and Exchange Board of India (SEBI) has imposed a penalty of Rs12 lakh on Roselabs Industries Ltd for not redressing investor complaints within a stipulated time and not submitting action taken report to the market regulator, reports PTI.
"...hereby impose a penalty of Rs12 lakhs on the noticee (Roselabs Industries) for not redressing investor grievances within the time specified and not submitting Action Taken Report within the time specified in the specified format," SEBI said in its order today.
SEBI had alleged that 24 grievances were pending against Roselabs Industries from far back as 1999.
In this regard, the regulator given the company a time of 15 days to redress the complaints.
SEBI had also asked the Roselabs Industries to submit the reasons for such pendency and what actions have been taken by the firm to resolve the grievances.
The company was further advised to remain present on 9 March 2011 at SEBI's office along with Action Taken Report in respect of the grievances.
However, Roselabs Industries had neither provided the information sought nor had attended the meeting, SEBI said.
The regulator observed that the number of investor grievances against the company had increased to 33 as on 21 August 2012.



Vaibhav Dhoka

5 years ago

Will SEBI dare to take action against Kotak Securities Ltd,for violating regulation?

Trio, including OBC officer, gets jail for Rs8 crore bank fraud

A special court imprisoned the three, including one officer from Oriental Bank of Commerce, for cheating the bank to nearly Rs8 crore through fraudulent manipulation of bank drafts

New Delhi: A former officer of Oriental Bank of Commerce (OBC) was sentenced to one-year imprisonment by a special court of Central Bureau of Investigation (CBI) for cheating the bank to the tune of nearly Rs8 crore through fraudulent manipulations of bank drafts, reports PTI.
The judge also sent Vikaspuri-resident Uma Bhatla and Manjeet Kumar, Proprietor of Shivani Jewellers at Karol Bagh, to three-year in jail.
All the three accused were imposed with fine as well.
"The investigation revealed that Ram Kumar, the then officer of Oriental Bank of Commerce, used to provide stolen book of blank demand drafts to Uma Bhatla who used to fabricate and forge these drafts with high value amount and Manjeet Kumar used to get the amount of these drafts credited in his firm's bank account," a CBI spokesperson said.
The court has also declared two other persons, who are at currently absconding, as proclaimed offenders.


We are listening!

Solve the equation and enter in the Captcha field.

To continue

Sign Up or Sign In


To continue

Sign Up or Sign In



The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)